Abstract
New agents for the treatment of myeloma have individual and class effects that advanced practitioners need to know about when helping to keep their patients on treatment regimens. At JADPRO Live, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD, reviewed recent advances in induction regimens, treatment selection at relapse, and considerations when treating bone complications and amyloidosis.
